The vector of anti-CD33 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD33. The T cells are genetically modified through transduction with a lentiviral vector expressing a bicistronic construct which self-cleaves at the 2A site to yeild TiP fused to CD3ζ signaling domain and a 1st generation CD33 CAR with TetR as its endodomain. The CAR-T function can be controlled by tetracycline through competitive binding of TetR with Tip. And the vector product was designed for the treatment of acute lymphoid leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-T-3-M311-2XZ||Anti-CD33 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1|
|CAR-MZ158||Anti-CD33 (DRB2) h(CD28-CD3ζ) CAR, pCDCAR1|
|CAR-LC196||Anti-CD33 (m2H12) h(41BB-CD3ζ) CAR, pCDCAR1|
|CAR-T-1-M311-Z||Anti-CD33 scFv h(CD3ζ) CART, pCDCAR1|
|VP-CAR-LC675||Lenti-CD33 CAR (scFv-41BB-CD3ζ, My9-6) Viral Particle|
|VP-CAR-LC103||Lenti-CD33 CAR (scFv-CD4-CD3ζ, CAMPATH-1H) Viral Particle|
|CAR-LC155||Anti-CD33 h(CD28-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC104||Lenti-CD33 CAR (scFv-CD8-CD3ζ, CAMPATH-1H) Viral Particle|
|CAR-LC194||Anti-CD33 (M195) h(41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC673||Lenti-CD33 CAR (scFv-41BB-CD3ζ, DRB2) Viral Particle|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved